Regenity Biosciences Completes First Surgery with RejuvaKnee™, Pioneering Meniscal Repair Innovation

Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio company, today announced the successful completion of the first surgery using RejuvaKnee™, a groundbreaking collagen-based meniscal implant designed to be implanted arthroscopically to reinforce and repair soft tissue injuries of the meniscus.

This milestone marks a pivotal moment in the evolution of meniscal repair treatments and highlights Regenity’s commitment to advancing patient outcomes through innovative regenerative solutions.

Paul Fleissner, MD, an orthopedic surgeon at the Crystal Clinic in Akron, OH, performed the surgery utilizing the RejuvaKnee™ implant to treat a college-aged athlete suffering from chronic pain following a prior meniscectomy. “I believe the RejuvaKnee™ implant has the potential to be a game-changer for meniscal restoration, especially for younger patients under forty seeking the most durable procedure,” said Dr. Fleissner. “The device offers excellent handling properties, is user-friendly for surgeons, and serves as a convenient ‘off-the-shelf’ solution for those who have irreparable tears or have previously lost meniscal tissue.”

RejuvaKnee™ is designed to facilitate the regeneration of native meniscal tissue, enabling a more complete recovery as compared to removing or replacing the meniscus. In a 12-month animal study, the implant demonstrated the ability to regenerate meniscal tissue that withstands full weight-bearing within three months, restoring the knee’s normal range of motion.1 These outcomes were superior to standard meniscectomy or allograft transplantation [in the animal study], providing a promising new option for patients with meniscal injuries.2

“The first surgery using RejuvaKnee™ is another meaningful milestone for Regenity, highlighting our mission to improve patient outcomes through regenerative medicine,” said Shawn McCarthy, CEO of Regenity Biosciences. “With RejuvaKnee™, we’re helping patients restore quality of life through tissue regeneration. This innovation underscores our leadership commitment to advancing next-generation solutions in Sports Medicine and making what should be a patient’s first surgery last.”

As the only FDA-cleared regenerative implant device for meniscal repair on the market, RejuvaKnee™ represents a significant innovation in orthopedic surgery and offers new hope to patients seeking a more comprehensive recovery.

Footnotes:

  1. Regenity Data on File, 2024
  2. Animal results do not necessarily translate to clinical results.